{
    "nctId": "NCT05374915",
    "briefTitle": "Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)",
    "officialTitle": "An Open-Labeled, Single Arm Phase 2 Efficacy and Safety Study of REM-001 Photodynamic Therapy (PDT) for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) That is Refractory or Not Eligible for Radiotherapy or Surgery",
    "overallStatus": "RECRUITING",
    "conditions": "Cutaneous Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Best Overall Objective Response Rate (bORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult participants 18 years of age or greater.\n* Participants able and willing to sign informed consent.\n* Histopathologically confirmed breast cancer metastasis to the skin.\n* Cutaneous metastasis not suitable for surgical resection.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n* Symptomatic lesions (including discomfort, pain, discharge, ulceration).\n* Cutaneous, subcutaneous soft tissue, or superficial lymphatic metastasis that is amenable to PDT:\n\n  * Lesion(s) \\> 10 mm and \\< 60 mm in longest dimension.\n  * Lesion(s) exhibit at least one of the following symptoms: ulcerated, bleeding, discharging, itchy, painful.\n  * Judged by investigator as eligible for PDT.\n* Participants are radiotherapy refractory (have received a radiation dose of 60 gray (Gy) or greater to the ipsilateral thorax) or are not otherwise amenable to radiotherapy.\n* Disease progression on at least 2 courses of systemic therapy:\n\n  * HR positive/HER2 negative participants: should be refractory to endocrine therapy (at least 2 different regimens including at least one CDK4/6 inhibitor). Maintenance endocrine therapy at the clinician's discretion is allowed.\n  * HER2 positive participants should have had disease progression on at least 2 different regimens of HER2 targeted therapies. Maintenance therapy on trastuzumab (HERCEPTIN\u00ae) is allowed.\n* Participants must have stable or responding systemic disease for at least 3 months at screening:\n\n  * If participants are on systemic therapy for 3 months at enrollment, it must be one from the Treatments of Physician's Choice (TPC) list, as follows: eribulin mesylate (Halaven\u00ae); capecitabine (Xeloda\u00ae); Gemcitabine (Gemzar\u00ae); a taxane \\[either docetaxel (Taxotere\u00ae), nab-paclitaxel (Abraxane\u00ae), or paclitaxel (Taxol\u00ae)\\]; vinorelbine (Navelbine\u00ae); an antibody-drug conjugate \\[either sacituzumab-govitecan (Trodelvy\u00ae), trastuzumab-deruxtecan (Enhertu\u00ae), or ado-trastuzumab emtansine (KADCYLA\u00ae)\\]; pembrolizumab (Keytruda\u00ae); or carboplatin (Paraplatin\u00ae), or\n  * Patients who are intolerant to chemotherapy will also be eligible, if they have stable or responding systemic disease for at least 3 months without TPC treatment at screening.\n* Participants with stable or responding systemic disease with no current plans to change or modify their TPC regimen while receiving study treatment.\n* Adequate renal function, as evidenced by estimated glomerular filtration rate (eGFR) \\> 45 mL/min/1.73 m2 using the CKD-EPI Creatinine Equation without race.\n* Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) \u2265 1.5 \u00d7 10\\^9/L, hemoglobin \u2265 8.5 g/dL and platelet count \u2265 100 \u00d7 10\\^9/L; INR \\< 1.5.\n* Adequate liver function as evidenced by bilirubin \u2264 2.0 times the upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) \u2264 3 \u00d7 ULN (in the case of liver metastases \u2264 5 \u00d7 ULN) \\[Participants with known Gilbert's Syndrome who have serum bilirubin \\< 1.5 x ULN (NCI CTCAE v5.0 Gr 2) may be enrolled\\].\n* QTCF \\< 470msec on baseline ECG\n* Woman of childbearing potential (WOCBP) must have a negative serum pregnancy test documented within 7 days prior to registration and must agree to practice adequate contraception\n* Male patients must be sterile or willing to use an approved method of contraception from the time of treatment with REM-001 until 90 days after study drug treatment.\n\nExclusion Criteria:\n\n* Participants who have received local cryotherapy, radiotherapy, intra-lesional chemotherapy, systemic or topical PDT, or surgery to study lesion fields within the past 12 weeks.\n* Participants with progressive brain or subdural metastases, or leptomeningeal disease.\n* Participants with previously treated brain or subdural metastases may participate provided:\n\n  * Previously treated brain metastases are stable and without evidence of progression, as determined by contrast-enhanced CT or MRI brain scan, for at least 4 weeks prior to the first dose of study treatment.\n  * There is no evidence of new brain metastases\n  * They have completed local therapy and discontinued the use of corticosteroids for this indication for at least 4 weeks prior to first dose of study treatment.\n  * Any neurologic symptoms attributed to brain metastases must have been stable for at least 4 weeks prior to study enrollment\n* History of allergic or hypersensitivity reactions to light, egg proteins or egg yolk; history of porphyria, systemic lupus erythematosus, or xeroderma pigmentosum.\n* Known disorder of lipoprotein metabolism or clearance (cholesterol\\> 400 mg/dl, and/or triglycerides \\> 500 mg/dl).\n* Participants who have received investigational agents within the past 4 weeks or within 4 half-lives of the investigational agent (whichever is shorter) before the first study drug dose.\n* Participants with inflammatory breast cancer.\n* Known human immunodeficiency virus (HIV) infection with detectable virus titer.\n* Active or chronic hepatitis B or C infection.\n* Active or ongoing infection requiring systemic treatment.\n* Participants who have undergone major surgery within 4 weeks of study treatment, or have planned surgery within 4 weeks of anticipated initiation of treatment with REM-001 therapy.\n* Participants with otherwise unexplained weight loss (\\> 10% body weight) in the last 30 days prior to Screening.\n* History of other malignancy treated with curative intent within the last 3-5 years. Exceptions are: Curatively treated basal cell/squamous cell skin cancer; carcinoma in situ of the cervix; superficial transitional cell bladder carcinoma\n* Patients with other major or uncontrolled medical conditions, e.g., myocardial infarction or New York Heart Association (NYHA) Class III/IV heart failure within the last 6 months, stroke, uncontrolled diabetes, uncontrolled autoimmune disease.\n* WOCBP that is pregnant or breast-feeding, or planning to become pregnant or breast-feed during protocol treatment and for 3 months after last dose of REM-001 therapy.\n* WOCBP unwilling to use effective contraception during protocol treatment and for 3 months after last dose of REM-001 therapy.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}